Clinical Trial Update: Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Orelabrutinib followed by response-adapted ultra-low-dose 4 Gy radiation as first-line therapy for mucosa-associated lymphoid tissue ly…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma
• Mucosa-associated Lymphoid Tissue Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: Fudan University | Conditions: Lymphoma, B-Cell, Marginal Zone | Phase 2 | Status: ACTIVE_NOT_RECRUITING